Inclusion Criteria:

          -  Histopathologically confirmed diagnosis of metastatic advanced cutaneous squamous cell
             carcinoma.

          -  History of solid-organ transplant requiring immunosuppression

          -  Progression of disease with estimated glomerular filtration rate (EGFR)-directed
             therapy

          -  Age ≥ 18 yrs

          -  Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

          -  Karnofsky Performance Status Scale (KPS) ≥60%, Eastern Cooperative Oncology Group
             (ECOG) ≤2

          -  No prior Janus kinase (JAK) Inhibitor therapy

          -  Adequate organ function

          -  All clinically significant toxicities from prior systemic therapy must be ≤ Grade 1
             (with the exception of alopecia, and peripheral neuropathy, which may be ≤ grade 2).

          -  Subjects must agree to undergo tumor biopsies until biopsies have been obtained from
             10 subjects (i.e., biopsies are required in at least the first 10 enrolled subjects,
             or until a goal of 10 study biopsies are obtained). Subjects in whom a biopsy is
             technically not feasible or in whom would result in unacceptable risk in the opinion
             of the investigator, may be exempted from the biopsy requirement with discussion with
             the principal investigator.

          -  Negative pregnancy test for women of child bearing potential

          -  Ability to take oral medications

          -  Adequate marrow function:

               -  Absolute neutrophil count (ANC) ≥1000 /mm3

               -  Platelet count ≥50,000/mm3

               -  Hemoglobin ≥8.0g/dL (not requiring transfusion in the past 2 weeks)

        Exclusion Criteria:

          -  At least 21 days must have elapsed since the last dose of systemic chemotherapy or
             immunotherapy and the first dose of study drug.

          -  At least 14 days must have elapsed since the last dose of radiation therapy and the
             first dose of study drug.

          -  Patients who have previously been treated with a JAK inhibitor.

          -  Patients who are receiving any other investigational agents concurrently.

          -  Patients who have had recent major surgery within a minimum 4 weeks prior to starting
             study treatment, with the exception of surgical placement for vascular access.

          -  Patients with a history of allergic reactions attributed to compounds of similar
             chemical or biologic composition to ruxolitinib.

          -  Patients with symptomatic or growing brain metastases. Patients with brain metastases
             that have been treated and have remained stable for at least one month prior to
             initiation of study therapy are eligible.

          -  Concurrent use of strong CYP3A4 or CYP3A4 substrate drugs with a narrow therapeutic
             range within 14 days or 5 drug half-lives, whichever is longer, before start of study
             drug. A list of strong CYP3A4 and 2C8 inhibitors and inducers can be found in Appendix
             A.

          -  HIV-positive patients on combination antiretroviral therapy are ineligible because of
             the potential for pharmacokinetic interactions with ruxolitinib. In addition, these
             patients are at increased risk of lethal infections when treated with marrow-
             suppressive therapy.

          -  Subjects with known active hepatitis B or C, or chronic hepatitis B or C requiring
             treatment with antiviral therapy.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Patients being actively treated for a second malignancy.